Logo
x

Search

Subscribe Now

metastatic castration-resistant prostate cancer

AstraZeneca and MSD Report Results of Lynparza in P-III PROfound Study for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and MSD Report Results of Lynparza in P-III PROfound Study for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant...

  • April 24, 2020
Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men

Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men

  • November 27, 2019
Janssen's Niraparib Receives the US FDA's Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer

Janssen's Niraparib Receives the US FDA's Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer

  • October 4, 2019
Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castrate-Resistant Prostate Cancer in Men

Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castra...

  • August 8, 2019
AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Mutation

AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with...

  • August 7, 2019
Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

  • May 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.